Home » Newsletters » BioWorld Science

BioWorld Science

Dec. 19, 2011

View Archived Issues

New agents target pathways involved in antipsychotic drug response

New candidate immunotherapies for ovarian cancer developed in Japan

Results presented from pilot study of Panvac vaccine

First-in-class mitotic kinase inhibitor shows anticancer properties

New antimicrobials show promise to treat urinary tract infections

Vertex patents new ATR inhibitors for cancer

BioSante Pharmaceuticals reports new phase III LibiGel data

Endocyte's PRECEDENT trial results confirmed by supplemental analyses

FDA grants orphan drug status to Pinnacle Biologics product

Novel PRCP inhibitors discovered at Merck & Co.

Array BioPharma patents new GPR119 receptor agonists

Takeda synthesizes novel TGFR-1 inhibitors

Merck & Co. reports new antihypertensive drugs

Gilead Sciences claims new antiviral products

NeuroSearch's SK channel research passed to new spin-out

Novartis Pharma stops clinical development of SMC-021

Treatment begins in phase III Benlysta trial

Trillium set to begin phase I TTI-1612 trial in Canada

Novartis' third phase III Gilenya study confirms previous encouraging outcomes

Soligenix begins to develop next-generation anthrax vaccine

AtheroNova plans IND submission for AHRO-001

FDA sets action date for Dymista NDA

Isis Pharmaceuticals provides update on NDA submission for mipomersen sodium

Prana Biotechnology begins recruitment in phase II PBT-2 trial

Hybrigenics completes enrollment in phase II inecalcitol trial

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 5, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 5, 2025.
Mesothelin is biomarker, potential target in arthritic bone damage
BioWorld Science
In a recent study published in Cell Reports Medicine, researchers from the Institute of Chinese Materia Medica of the China Academy of Chinese Medical Sciences...
Epigenetic technology could eliminate misfolded prion proteins
BioWorld Science
The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...
CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials
BioWorld
A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...